AK-2292 is a selective PROTAC designed to degrade STAT5 proteins, effectively promoting their degradation in both in vitro and in vivo settings. This compound demonstrates potential in inducing tumor regression in models of acute and chronic myeloid leukemia. Additionally, AK-2292 features an alkyne group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-bearing molecules.
Usually ships within 24 hours.